Question 1

What is the standard tirzepatide escalation schedule?

Accepted Answer

Start 2.5 mg SC weekly for 4 weeks (initiation; not therapeutic, purely to minimize GI side effects). Escalate 2.5 mg every 4 weeks: 5 → 7.5 → 10 → 12.5 → 15 mg. The therapeutic range begins at 5 mg; most patients reach peak efficacy at 10, 12.5, or 15 mg depending on indication and tolerance. Slower titration (every 6–8 weeks) is reasonable if GI symptoms are severe.

Question 2

What's the difference between Mounjaro and Zepbound?

Accepted Answer

Same molecule, same pen, different label. Mounjaro is FDA-approved for type 2 diabetes (2022): Zepbound is approved for obesity / weight management (2023) and obstructive sleep apnea in adults with obesity (2024). Insurance coverage often differs by label. Off-label prescribing of Mounjaro for weight loss is common but creates insurance and compounding complications.

Question 3

How does tirzepatide compare to semaglutide?

Accepted Answer

Semaglutide is GLP-1 only. Tirzepatide is a dual GIP + GLP-1 agonist; the added GIP mechanism drives roughly one-third more weight loss head-to-head. SURMOUNT-5 MAINTAIN (2025, PMID 40353578) showed tirzepatide 15 mg beats semaglutide 2.4 mg in obesity, and SURPASS-2 (PMID 34170647) showed tirzepatide 15 mg beats semaglutide 1 mg in T2D (HbA1c −2.30% vs −1.86%, 5.5 kg greater weight loss). Side-effect profile is similar.

Question 4

What are the common side effects during escalation?

Accepted Answer

Nausea (30–40% at 15 mg during titration, resolves by 8–12 weeks), diarrhea (15–25%), vomiting (10–20%), constipation (15–20%, often alternating with diarrhea), dyspepsia (5–15%). Most are mild-to-moderate and titration-dependent. Hydration is the single most important counter-measure, AKI from dehydration is the most common reason for hospitalization. Hair shedding (telogen effluvium from rapid weight loss) is common, see the hair-loss protocol calculator.

Question 5

What are the serious safety signals I should know about?

Accepted Answer

(1) Gallbladder events (cholelithiasis, cholecystitis), a class effect of rapid weight loss; incidence ~1–2%. (2) Pancreatitis, rare but discontinue permanently if confirmed. (3) Delayed gastric emptying → anesthesia-aspiration risk: ASA/FDA 2023–2025 guidance recommends a 7-day pre-operative hold. (4) Hypoglycemia when combined with insulin or sulfonylureas. (5) Medullary thyroid carcinoma; boxed warning from rodent data; no elevated human signal in aggregate trial data. Baseline thyroid exam is reasonable; avoid in personal/family history of MTC or MEN-2.

Question 6

How much weight loss can I expect?

Accepted Answer

SURMOUNT-1 (PMID 35658024) at 72 weeks: 15 mg → −20.9% (non-diabetic obesity); 10 mg → −19.5%; 5 mg → −15.0%; placebo → −3.1%. The 176-week extension (PMID 39536238) showed durability with continued use. A rough heuristic, ~1.5–2 lbs/week during active titration, then slower, is useful for expectation-setting but not a planning tool; individual response varies widely with diet adherence, baseline BMI, and metabolic health. Talk to your provider about realistic goals.

Question 7

Who shouldn't take tirzepatide?

Accepted Answer

Personal or family history of medullary thyroid carcinoma (MTC). Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). History of pancreatitis (relative contraindication). Severe gastroparesis at baseline. Pregnancy and breastfeeding (no human data; stop at least 2 months before planned conception). Known hypersensitivity to tirzepatide or excipients.

Tirzepatide Dosage Chart